EUVIMEDEUVIMED entdecken
Crossref

A Randomized Euglycemic Clamp Study to Demonstrate Bioequivalence of Biosimilar and Reference Ultra‐Long‐Acting Insulin Degludec in Healthy Volunteers

Sergei Noskov, Ekaterina Koksharova, Anna Arefeva, Veniamin Banko, Kseniia Radaeva, Dmitrii Iliushchenko, Igor Makarenko, Roman Drai

Clinical Pharmacology in Drug Development · 2026-11 · 15 (11)

DOI: 10.1002/cpdd.70127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 20.11.2026. Verfasst von Sergei Noskov und 7 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulin degludec is an ultra‐long‐acting basal insulin analog characterized by a prolonged duration of action exceeding 42 h and a stable, peakless pharmacokinetic profile, designed to provide consistent glycemic control with reduced risk of hypoglycemia in patients with diabetes. This was a double‐blind, randomized, two‐period, crossover clamp study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of a potential biosimilar insulin degludec, along with safety profiles, compared with the reference product in healthy volunteers. A total of 50 healthy male volunteers completed euglycemic clamp procedures across both study periods. Blood samples were collected at predefined intervals up to 72 h postdose to assess PK parameters. Glucose levels were monitored at frequent intervals during the clamp period, with adjustments to the glucose infusion rate (GIR) to maintain the target euglycemic range. Insulin degludec quantification in serum was conducted using a validated bioanalytical method. PD assessment was based on GIR profiles, including total glucose infused and maximum GIR, during both 24‐h clamp periods. The geometric mean ratio for area under the concentration–time curve from time zero to the end of the dosing interval (AUC 0–T ) for the test and reference products fell within the predefined bioequivalence acceptance range of 80%–125%. Furthermore, the biosimilar demonstrated PK and PD profiles comparable to those of the reference insulin degludec. Both formulations exhibited similar safety profiles, with no clinically significant differences observed.

Zitieren

APA

Noskov, S., Koksharova, E., Arefeva, A., Banko, V., Radaeva, K., Iliushchenko, D., Makarenko, I., & Drai, R. (2026). A Randomized Euglycemic Clamp Study to Demonstrate Bioequivalence of Biosimilar and Reference Ultra‐Long‐Acting Insulin Degludec in Healthy Volunteers. Clinical Pharmacology in Drug Development, 15(11). https://doi.org/10.1002/cpdd.70127

Vancouver

Noskov S, Koksharova E, Arefeva A, Banko V, Radaeva K, Iliushchenko D, et al. A Randomized Euglycemic Clamp Study to Demonstrate Bioequivalence of Biosimilar and Reference Ultra‐Long‐Acting Insulin Degludec in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2026;15(11). doi:10.1002/cpdd.70127

BibTeX
@article{Noskov2026,
  author = {Noskov, Sergei and Koksharova, Ekaterina and Arefeva, Anna and Banko, Veniamin and Radaeva, Kseniia and Iliushchenko, Dmitrii and Makarenko, Igor and Drai, Roman},
  title = {A Randomized Euglycemic Clamp Study to Demonstrate Bioequivalence of Biosimilar and Reference Ultra‐Long‐Acting Insulin Degludec in Healthy Volunteers},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cpdd.70127}
}
Kostenlos starten →